$2.3M
1 filing since 2025 · latest Options filed
Tinos Therapeutics is a preclinical oncology company developing RNA-targeted cancer therapies. It was spun out of research at Brown University showing that cancer cells depend on the RNA demethylase FTO for survival, and it builds small-molecule inhibitors intended to destabilize tumor-driving RNA. Its lead TN01 series is at the pre-IND stage, aimed at glioblastoma, colorectal cancer, and AML.
What sets it apart
Targets RNA methylation rather than the protein or DNA layer, using an AI-assisted EpiCode platform to design first-in-class small-molecule FTO inhibitors.
A pre-IND series of small-molecule inhibitors of the RNA demethylase FTO, designed to destabilize the RNA that drives tumor survival.
